Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 19 for:    lyme antibody | Lyme Disease

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04863287
Recruitment Status : Active, not recruiting
First Posted : April 28, 2021
Last Update Posted : November 19, 2021
Sponsor:
Collaborator:
Celerion
Information provided by (Responsible Party):
MassBiologics

Brief Summary:

This is a research study of the investigational drug 2217LS in healthy volunteers. Investigational means 2217LS is a new drug that has not been approved for the treatment of any disease. 2217LS is human antibody designed to provide protection from Lyme disease. Lyme disease is a disease carried by infected ticks and can cause the infection to spread to the joints, heart and nervous system in humans.

This is the first time 2217LS will be given to humans. This is not a study of how well 2217LS works against Lyme disease. The only purposes of this study are to: 1) Learn about the safety and tolerability of a subcutaneous (SC [under the skin]) injection of 2217LS when administered to healthy volunteers. 2) Find out how much 2217LS is in the blood of healthy volunteers after receiving 2217LS SC.

In this study, groups of healthy volunteers will be given different doses of 2217LS by SC injection. Volunteers will stay in the study unit for a total of 4 overnights. The planned duration of participation is up to 14 months. Study personnel will monitor their safety using standard procedures like physical examinations, electrocardiograms, questions about possible side effects, blood and urine tests. The amount of 2217LS in their blood will also be measured.


Condition or disease Intervention/treatment Phase
Lyme Disease Biological: 2217LS Other: 0.9% Sodium Chloride (NaCl) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Randomized, partial-blind, placebo controlled, sequential, dose escalation study, consisting of four cohorts of 10 subjects. Each cohort will have a sentinel group consisting of 2 subjects randomized 1:1 to receive 2217LS or placebo. Sentinel subjects will be dosed first. If judged safe and well tolerated by the Principal Investigator (PI) and if the stopping rules have not been met, the remaining 8 subjects in the cohort will be randomized 7:1 to 2217LS or placebo, respectively and dosed no less than 24 hours after dosing of sentinel subjects has been completed.

For each cohort, safety and pharmacokinetic (PK) data will be reviewed by the PI, Independent Medical Monitor (IMM) and Sponsor prior to dosing the next cohort. A minimum of 7 days of safety data and available PK data from a minimum of 8 subjects from the preceding cohort must be reviewed. Dosing of the next cohort may proceed upon agreement between the PI, IMM and Sponsor, if the stopping rules have not been met.

Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Other
Official Title: A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (2217LS) Against Borrelia Burgdorferi (B. Burgdorferi) Outer Surface Protein A (OspA)
Actual Study Start Date : February 11, 2021
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lyme Disease

Arm Intervention/treatment
Experimental: 0.5 mg/kg of 2217LS
Single dose subcutaneous injection
Biological: 2217LS
Fully Human Monoclonal Antibody

Experimental: 1.5 mg/kg of 2217LS
Single dose subcutaneous injection
Biological: 2217LS
Fully Human Monoclonal Antibody

Experimental: 5 mg/kg of 2217LS
Single dose subcutaneous injection
Biological: 2217LS
Fully Human Monoclonal Antibody

Experimental: 10 mg/kg of 2217LS
Single dose subcutaneous injection
Biological: 2217LS
Fully Human Monoclonal Antibody

Placebo Comparator: 0.9% Sodium Chloride (NaCl)
Single dose subcutaneous injection
Other: 0.9% Sodium Chloride (NaCl)
Subcutaneous injection




Primary Outcome Measures :
  1. Safety and tolerability of a study treatment by number of adverse events reported [ Time Frame: Day 1 through Day 360 ]
    Adverse events will be assessed by targeted medical history, physical examination, and laboratory testing. Abnormal laboratory values constitute adverse events only if they induce signs or symptoms and/or require therapy that are new or enhanced from baseline. Injection site reactions (pain, tenderness, erythema/redness, and induration/swelling) will be evaluated pre-dose through Day 15. The reactions are rated Mild (Grade 1), Moderate (Grade 2), and Severe (Grade 3) according to FDA guidance for industry. Adverse events will be summarized by System Organ Class (SOC) using MedDRA.


Secondary Outcome Measures :
  1. Pharmacokinetics (PK) parameter: Maximum serum concentration observed (Cmax) of 2217LS [ Time Frame: 14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360 ]
    Serial measurements of 2217LS concentration in the serum.

  2. Pharmacokinetics (PK) parameter: Area under the curve (AUC) of 2217LS [ Time Frame: 14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360 ]
    Serial measurements of 2217LS concentration in the serum.

  3. Pharmacokinetics (PK) parameter: Serum half life (T 1/2) of 2217LS [ Time Frame: 14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360 ]
    Serial measurements of 2217LS concentration in the serum.

  4. Assessment of immunogenicity anti-drug antibodies (ADA) of 2217LS [ Time Frame: 10 Study Days - Day 1 Pre-Dose, Day 8 or 9, 14 or 15, 29, 60, 90, 120, 180, 240, 360 ]
    Serial measurements of 2217LS concentration in the serum.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Capable of giving written informed consent and able to effectively communicate with the Investigator and study personnel. A signed informed consent form (ICF) must be on file prior to initiating the screening procedures.
  2. Willing and able to complete all study requirements, restrictions, visits and procedures.
  3. Negative for serum anti-B. burgdorferi antibodies by an FDA approved modified two-tier ELISA test.
  4. Age 19 to 65 years, inclusive.
  5. Weight 50 kg to 105 kg, inclusive.
  6. Seated blood pressure is greater than 90/40 mmHg or less than 140/90 mmHg at the screening visit, and seated heart rate is higher than 40 bpm or lower than 99 bpm at the screening visit.
  7. Women of reproductive potential must agree not to become pregnant for at least 12 months after the study product administration. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel.
  8. Males of reproductive potential must use a barrier method of contraception during the course of the study.
  9. Screening laboratory values must meet the following criteria:

    • WBC > 3,900 and < 11,000/mm3
    • Platelets > 100,000/mm3
    • Hemoglobin > 10.5 gm/dl
    • Creatinine ≤ ULN
    • BUN ≤ ULN
    • AST ≤ ULN
    • ALT ≤ ULN
    • Alkaline Phosphatase ≤ ULN
    • Total Bilirubin < 1.5 x ULN AND Direct Bilirubin ≤ ULN
    • HgbA1c ≤ 6.4

Exclusion Criteria:

  1. Previous receipt of humanized or human monoclonal antibody whether licensed or investigational.
  2. Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen.
  3. Regular use of more than 20 cigarettes per day (or equivalent amount of nicotine containing product)
  4. Drug or alcohol abuse within previous 12 months or a positive screen within 24 hours of study product administration.
  5. History of a previous severe allergic reaction with generalized urticaria, angioedema or anaphylaxis.
  6. Any current medical or other condition that in the opinion of the PI would jeopardize the safety of the volunteer participating in the study.
  7. Clinically significant gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease, as determined by the PI. The investigator will consider all conditions, which could conceivably increase risk to the subjects, alter study drug metabolism, or jeopardize data integrity as clinically significant when making this determination.
  8. Physical finding on examination considered clinically significant such as murmur (other than functional), hepatosplenomegaly, lymphadenopathy or focal neurological deficit.
  9. Positive serum pregnancy test during screening or within 24 hours of study product administration, or an unwillingness to undergo pregnancy testing.
  10. Breast-feeding.
  11. Treatment with another investigational drug or other investigational intervention within 30 days of study drug dosing.
  12. Safety laboratory abnormalities at Screening or Day -1, which are clinically significant as determined by the PI.
  13. Tick bite within 4 weeks prior to screening.
  14. Receipt of any Lyme disease vaccine.

Abnormal ECG or laboratory parameters may be repeated once, if in the opinion of the PI, the results are due to technical factors or are inconsistent with the potential subject's medical evaluation.

Potential study subjects who met all inclusion and none of the exclusion criteria, but who, for personal or administrative reasons, were not included in a study cohort, may be rescreened if more than 30 days have passed since their previous screening. There are no restrictions on the number of re-screens permitted for these subjects.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04863287


Locations
Layout table for location information
United States, Nebraska
Celerion Inc.
Lincoln, Nebraska, United States, 68502
Sponsors and Collaborators
MassBiologics
Celerion
Layout table for additonal information
Responsible Party: MassBiologics
ClinicalTrials.gov Identifier: NCT04863287    
Other Study ID Numbers: MBL-LYME-20-01
First Posted: April 28, 2021    Key Record Dates
Last Update Posted: November 19, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MassBiologics:
LYME
Lyme bacteria
Borrelia burgdorferi (B. burgdorferi)
Human Monoclonal Antibody
Outer surface protein A (OspA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lyme Disease
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Borrelia Infections
Spirochaetales Infections
Tick-Borne Diseases
Vector Borne Diseases